Search

2024 SEP 14 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Fresh data on central nervous system agents are presented in a new [...]

2024 SEP 14 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on central nervous system agents. According to news [...]

The article provides a comparison between pharmacological interventions and surgery for the management of trigeminal neuralgia pain. Topics mentioned include a description of the etiology of trigeminal neuralgia, the implication of trigeminal neuralgia in dentistry, the different forms of surgical interventions, and the recommended drugs to help relieve pain symptoms experienced by patients.

2024 AUG 17 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in central nervous system agents. According to news [...]

2024 JUL 27 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Fresh data on Engineering - Crystal Engineering are presented in a new [...]

2024 JUN 15 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Nanotechnology - Nanoemulsions have been published. According to [...]

2024 MAY 11 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Fresh data on Nanotechnology - Photocatalytics are presented in a new report. [...]

2024 APR 6 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Researchers detail new data in Drugs and Therapies - Central Nervous System [...]

2024 MAR 30 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on otic antiinfectives have been published. According to news [...]

2024 FEB 17 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- New research on Drugs and Therapies - Central Nervous System Agents is [...]

2024 JAN 13 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Nanotechnology - Photocatalytics have been published. According to [...]

2024 JAN 6 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Drugs and Therapies - Central Nervous System Agents [...]

The provided document is a list of drugs associated with non-serious adverse events found in recent scientific literature. The list includes the drug names, the adverse events, and the number of cases reported. Some examples of adverse events include tuberculosis associated with Adalimumab and Anakinra, hypersensitivity associated with Amoxicillin/clavulanic acid, and dizziness, nausea, pruritus, and urticaria associated with Antivenin PANAF. The list covers a wide range of drugs and adverse events, providing valuable information for researchers studying specific topics. [Extracted from the article]

This document provides a list of drugs associated with non-serious adverse events identified in scientific literature over the past week. The table includes the names of the drugs, the adverse events reported, and the number of cases. Some of the adverse events mentioned include signs, symptoms, ill-defined conditions, malakoplakia, dyspnea, gastrointestinal disorders, hypersensitivity, thyroid disorders, granuloma, immunological disorders, skin disorders, and more. [Extracted from the article]

A 36-year-old man with global developmental delay and medically refractory epilepsy exhibited lack of efficacy during treatment with carbamazepine and levetiracetam for seizures. Despite controlling some seizures, he continued to experience recurrent spells of abdominal pain and loud screams, indicating a lack of efficacy to the medications. Further diagnosis revealed seizure mimics including porphyria, leading to changes in treatment and eventual confirmation of acute intermittent porphyria through genetic testing. [Extracted from the article]

A 48-year-old woman with relapsing-remitting multiple sclerosis experienced various toxicities during treatment with carbamazepine, interferon-beta-1a, and teriflunomide. She developed drug rash with eosinophilia and systemic symptoms syndrome with carbamazepine, aphthous ulcer, arthralgia, and flu-like symptoms with interferon-beta-1a, and acute ischemic stroke with teriflunomide. After appropriate treatment and changes in therapy, her condition improved, and she was eventually switched to ocrelizumab. [Extracted from the article]

A retrospective study described a case of a boy who developed drug resistance to valproate for epileptic seizures and an allergic reaction to carbamazepine. The boy initially responded well to valproate but later became resistant to it, leading to the use of various other antiseizure medications. The best control of his seizures was achieved with sodium channel blockers and sulthiame, and he is currently on a regimen of lamotrigine, sulthiame, and lacosamide. Additionally, he has hypothyroidism and is being treated with levothyroxine. [Extracted from the article]

A 72-year-old man with a history of osteoradionecrosis and adenoid cystic carcinoma experienced lack of efficacy with gabapentin and carbamazepine for neuropathic pain. Despite treatment, he continued to experience pain, including allodynia. After being diagnosed with surgical complex regional pain syndrome, he underwent various treatments, including stellate ganglion block and spinal cord stimulator implantation, which helped improve his pain. [Extracted from the article]

A 19-year-old man developed toxidermia while being treated with carbamazepine for bipolar disorder. The man had a history of diabetes and had previously been treated with risperidone. After developing a rash, carbamazepine was discontinued, and the man was treated with anti-histamines and corticosteroids. A pharmacovigilance opinion concluded that carbamazepine was responsible for the toxidermia, leading to its contraindication for further use in the patient, who was then put on sodium-valproate with good tolerance. [Extracted from the article]

A retrospective study examined 23 patients with drug-resistant epilepsy who experienced various symptoms while being treated with multiple medications. Of the 17 patients described in the study, they exhibited distractibility, irritability, headache, drowsiness, or fatigue during treatment with brivaracetam. These patients also did not respond to other medications such as lamotrigine, carbamazepine, and phenobarbital. It is important for individuals with drug-resistant epilepsy to be aware of potential side effects and lack of efficacy when considering different treatment options. [Extracted from the article]

This article describes three case reports of patients, including two boys and one girl, who experienced lack of efficacy or adverse reactions to various medications. The first case involved a 14-year-old boy who initially received carbamazepine for complex partial seizures but developed Stevens-Johnson syndrome. He was later diagnosed with ADHD and OCD and experienced worsened movements and agitation with atomoxetine, fluoxetine, and risperidone. The second case involved a 10-year-old boy with an obsessive-compulsive spectrum disorder who did not respond to fluoxetine and developed increased tics. The third case involved a 16-year-old girl with Tourette syndrome who experienced worsening mood disturbances and tics with risperidone and sodium valproate. Adjustments to their medications and additional therapies were made to manage their conditions. [Extracted from the article]

A 63-year-old man experienced lack of efficacy while being treated with lacosamide for post-stroke epilepsy. The patient had a history of dyslipidaemia, abdominal aortic aneurysm, and diabetes mellitus. Despite being initially treated with levetiracetam and later switched to lacosamide, the patient's involuntary utterances did not decrease. He was referred for psychiatric consultation and ultimately treated with carbamazepine, which successfully resolved his aggression. [Extracted from the article]

A 13-year-old boy experienced a lack of efficacy during treatment with valproate, carbamazepine, and lacosamide for generalised tonic-clonic seizures. Despite receiving these medications, his seizures worsened and he developed progressive weakness in his left arm. He was eventually diagnosed with Rasmussen's encephalitis and underwent a right functional hemispherotomy, which successfully stopped his seizures. Although he experienced a temporary right third nerve palsy after the surgery, he has remained seizure-free for the past six months. [Extracted from the article]

A 23-year-old woman with neurodevelopmental abnormalities and intellectual disability experienced generalized tonic-clonic seizures (GTCS). She initially responded well to carbamazepine treatment and remained seizure-free for over 7 years. However, at 23 years old, the GTCS recurred and carbamazepine was ineffective in controlling the seizures. The woman was then treated with levetiracetam, lacosamide, and perampanel, but none of these medications were successful in achieving seizure control. Further examination revealed a genetic variant that may contribute to her condition. [Extracted from the article]

A case report published in Reactions Weekly describes a patient who experienced vertigo and lack of efficacy while being treated with carbamazepine for trigeminal neuralgia. The patient's condition worsened despite the medication, indicating that it was not effective. As a result, the patient's medication was adjusted. Eventually, the patient developed vertigo as a side effect of long-term carbamazepine use. The report does not provide specific details about the patient's age, sex, dosage, duration of treatment, or outcome. [Extracted from the article]

In a retrospective study, two cases were described of patients who experienced adverse reactions or lack of effectiveness while being treated with carbamazepine for myogenic tinnitus. The first patient developed a drug rash and discontinued carbamazepine therapy. The second patient, a 33-year-old woman, did not experience any improvement in her tinnitus despite receiving carbamazepine. She eventually underwent multiple surgeries, and her tinnitus disappeared after the third surgery. However, it is important to note that the tinnitus did not reappear during the 13-month follow-up period. [Extracted from the article]

A 67-year-old man experienced drowsiness and throat congestion while being treated with carbamazepine for glossopharyngeal neuralgia (GPN). Initially, he was prescribed 100mg of carbamazepine, but the pain persisted and he developed side effects. The dosage was increased to 100mg twice a day, which reduced the pain but the side effects remained. Eventually, he underwent microvascular decompression surgery, which successfully alleviated the pain. After the surgery, he no longer experienced pain or sinus arrest and was able to discontinue carbamazepine. [Extracted from the article]

A case report published in Reactions Weekly describes the development of chronic subdural hematomas in a 3-year-old girl who was receiving antiplatelet therapy with aspirin and dipyridamole, as well as anticoagulant therapy with warfarin. The girl had been diagnosed with Schimke immunoosseous dysplasia and had a history of transient ischemic attacks, partial epilepsy, and cerebral atrophy. The occurrence of chronic subdural hematomas was considered to be an adverse effect of the medications. Treatment with aspirin and warfarin was discontinued, and the girl later died at the age of 5 years and 9 months. [Extracted from the article]

This article discusses two case reports of women aged 72-74 years who experienced adverse reactions to carbamazepine and oxcarbazepine while being treated for trigeminal neuralgia. The first patient did not respond to the medication, while the second patient developed an allergy. Both patients had a history of nonacoustic cerebellopontine angle tumors and underwent retromastoid craniectomy. The article does not provide specific details about the dosages, routes, durations of treatment, or outcomes. [Extracted from the article]

A retrospective analysis of 112 question-and-answer pairs from the Norwegian Regional Medicines Information and Pharmacovigilance Centres database revealed 11 cases of newborns experiencing various toxicities after being exposed to antiepileptic drugs or codeine through breastfeeding. The newborns exhibited symptoms such as sedation, drowsiness, watery stools, lack of weight gain, feeding problems, and tremors. The mothers were taking medications such as levetiracetam, carbamazepine, lamotrigine, valproate, topiramate, phenobarbital, or codeine while breastfeeding. In some cases, breastfeeding was discontinued. [Extracted from the article]

A recent report from researchers at Facultad de Ingenieria in Cali, Colombia, explores the use of hydrodynamic cavitation intensified with ozone and UV radiation to decrease the concentration of carbamazepine in aqueous solution. Carbamazepine is a drug used for the treatment of epilepsy and mood disorders, but its presence in bodies of water can have negative impacts on the environment. The study found that while the process was able to degrade carbamazepine to some extent, it did not completely mineralize the compound. This research provides valuable insights into potential methods for treating carbamazepine in water resources. [Extracted from the article]

2023 JUL 15 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on central nervous system agents. According to news [...]

2023 JUL 8 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Researchers detail new data in Nanotechnology - Photocatalytics. According to news reporting [...]

2023 JUL 1 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in bipolar disorders. According to news reporting from [...]

2023 JUN 24 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Researchers detail new data in Nanotechnology - Photocatalytics. According to news reporting [...]

2023 JUN 10 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Researchers detail new data in central nervous system agents. According to news [...]

2023 APR 1 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A new study on Drugs and Therapies - Central Nervous System Agents [...]

2023 APR 1 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Researchers detail new data in central nervous system agents. According to news [...]

2023 MAR 4 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Drugs and Therapies - Central Nervous System Agents [...]

A retrospective study in China examined 16 cases of drug-induced liver injury (DILI) in patients treated with various medications. The patients experienced elevated levels of liver enzymes and other markers, leading to a diagnosis of DILI. The medications implicated in the cases included cetirizine, allopurinol, paracetamol, rifampicin, isoniazid, ethambutol, pyrazinamide, fluconazole, mecobalamin, betahistine, carbamazepine, levonorgestrel, ethinylestradiol, ranitidine, and thiamazole. In some cases, DILI progressed to acute liver failure. This study highlights the potential for liver injury associated with these medications and the importance of monitoring liver function during treatment. [Extracted from the article]

A retrospective study in China examined 16 cases of drug-induced liver injury (DILI) in patients treated with various medications. The patients experienced elevated levels of liver enzymes and other markers, leading to a diagnosis of DILI. The medications implicated in the cases included cetirizine, allopurinol, paracetamol, rifampicin, isoniazid, ethambutol, pyrazinamide, fluconazole, mecobalamin, betahistine, carbamazepine, levonorgestrel, ethinylestradiol, ranitidine, and thiamazole. In some cases, DILI progressed to acute liver failure. This study highlights the potential for liver injury associated with these medications and the importance of monitoring liver function during treatment. [Extracted from the article]

2023 JAN 14 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on central nervous system agents have been presented. According to [...]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 35-year-old man exhibited lack of efficacy during treatment with carbamazepine for trigeminal neuralgia. He had trigeminal neuralgia and was being treated with carbamazepine [route and dosage not stated]. Despite being treated with high dose of carbamazepine, he experienced severe pain (lack of efficacy). Later, et al. hemifacial spasm was noted and he underwent microvascular decompression with retrosigmoid craniotomy. [Extracted from the article]

The article offers information on a rare case of carbamazepine-induced malignant hypertension reported in Nepal. Topics discussed include the severe adverse effects of carbamazepine; the case details of a patient who developed hypertension due to the drug; and the management and resolution of the condition upon discontinuation of carbamazepine.

An adult man with a history of severe intellectual developmental disorder and behavioral issues was treated with multiple medications, including quetiapine, valproic acid, and zuclopenthixol, but experienced sedation, extrapyramidal side effects, and lack of efficacy. He was then switched to off-label treatment with clozapine, which initially caused hypersalivation but subsided with increased dosage. Throughout 1.5 years of clozapine therapy, the man showed improvements in aggression, body mass index, blood glucose levels, and overall quality of life. Due to these positive outcomes, the decision was made to continue with clozapine therapy. [Extracted from the article]

A single-center retrospective cross-sectional study was conducted to examine cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) in 23 patients between January 2014 and September 2020. The study found that patients developed DRESS while being treated with various drugs, including amlodipine, carbamazepine, ciprofloxacin, diosmin/hesperidin, hydroxychloroquine, and lamotrigine. The study identified the causative drugs for DRESS in each case, with lamotrigine and carbamazepine being implicated in one case, hydroxychloroquine in another, ciprofloxacin in another, amlodipine in another, and diosmin/hesperidin in another. The study did not provide specific details about the patients' ages, sexes, treatment durations, or outcomes. [Extracted from the article]

This article presents two case reports of patients in their 70s who were diagnosed with trigeminal neuralgia and experienced adverse reactions and lack of efficacy with various medications. In the first case, a woman developed agranulocytosis and facial edema while taking carbamazepine and pregabalin, and later experienced lack of efficacy with baclofen and mirogabalin. In the second case, a man did not experience improvement with carbamazepine. Both patients eventually underwent trigeminal nerve vascular decompression surgery with successful outcomes. [Extracted from the article]

An 11-year-old boy with type 1 diabetes mellitus was brought to the hospital in an unconscious state. He had experienced severe hypoglycemia and multiple seizures prior to admission. Despite receiving treatment with glucose, midazolam, and various antiepileptic drugs, his condition did not improve. He was eventually diagnosed with hypoglycemic encephalopathy and epilepsy. Despite multiple treatment regimens, the boy remained refractory to the medications and experienced significant intellectual disability as a result. The lack of efficacy with the antiepileptic drugs was considered in his case. [Extracted from the article]

A case report published in Reactions Weekly describes a patient who developed drug-induced epidermal necrolysis (DEN) while being treated with carbamazepine. The study, which involved 125 patients, took place between January 2000 and 2019. The patient's age, sex, and specific treatment details were not provided in the report. However, it was noted that the patient was a carrier of HLA and was diagnosed with DEN as a result of carbamazepine treatment. [Extracted from the article]

A 24-year-old man experienced withdrawal symptoms in the form of catatonia while being treated with carbamazepine and risperidone for juvenile myoclonic seizures. The man had a genetic condition and comorbid intellectual disability, bipolar mood disorder, autism spectrum disorder, and generalized tonic-clonic seizures. Prior to hospitalization, his carbamazepine therapy was stopped due to behavioral issues, and he started receiving treatment with risperidone, valproic acid, and lithium. He was diagnosed with withdrawal symptoms in the form of catatonia, and after receiving electroconvulsive therapy, his symptoms improved. He was discharged with medication and remained free of catatonia symptoms after two years of treatment. [Extracted from the article]